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Abstract
Formulations of chimeric dengue vaccine (DENVax) viruses containing the pre-membrane (prM) 
and envelope (E) genes of serotypes 1–4 expressed in the context of the attenuated DENV-2 
PDK-53 genome were tested for safety, immunogenicity and efficacy in interferon receptor knock-
out mice (AG129). Monovalent formulations were safe and elicited robust neutralizing antibody 
responses to the homologous virus and only limited cross-reactivity to other serotypes. A single 
dose of monovalent DENVax-1, -2, or -3 vaccine provided eighty or greater percent protection 
against both wild-type (wt) DENV-1 (Mochizuki strain) and DENV-2 (New Guinea C strain) 
challenge viruses. A single dose of monovalent DENVax-4 also provided complete protection 
against wt DENV-1 challenge and significantly increased the survival times after challenge with 
wt DENV-2. In studies using tetravalent mixtures, DENVax ratios were identified that: (i) caused 
limited viremia, (ii) induced serotype-specific neutralizing antibodies to all four DENV serotypes 
with different hierarchies, and (iii) conferred full protection against clinical signs of disease 
following challenge with either wt DENV-1 or DENV-2 viruses. Overall, these data highlight the 
immunogenic profile of DENVax, a novel candidate tetravalent dengue vaccine and the advantage 
of sharing a common attenuated genomic backbone among the DENVax monovalent vaccines that 
confer protection against homologous or heterologous virus challenge.
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Dengue viruses (DENV) are among the most common and important causative agents of 
emerging mosquito-borne viral disease in humans today [1,2]. These viruses belong to the 
family Flaviviridae and comprise four distinct antigenic serotypes (DENV-1 through 
DENV-4) that are transmitted to humans primarily by Aedes aegypti mosquitoes. Several 
factors such as travel, demographic and economic changes and the geographical expansion 
of the mosquito vector have contributed to the dramatic spread of the disease [3,4]. Infection 
with DENV leads to dengue fever (DF) of varying severity. The most severe consequences 
of infection – dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) – are 
life threatening. It is estimated that DENV cause 50–100 million cases of debilitating DF, 
500,000 cases of DHF/DSS, and more than 20,000 deaths each year [4,5].
Host immune responses play a critical role in the resolution and protection against primary 
and secondary DENV infections. After primary infection IgG antibodies predominantly 
recognize the virus structural and non-structural proteins [6]. Following reinfection with the 
same DENV serotype, the humoral immune response has broader specificity and the 
antibodies are cross-reactive with other DENV serotypes since they are structurally related 
[6]. However, the immune response to DENV may also contribute to the severity of disease 
due to pre-existing immunity following a secondary infection with a different DENV 
serotype [7–9]. It is believed that at least in part this phenomenon is a result of the presence 
of sub neutralizing anti-DENV antibody levels that exacerbate disease by increasing 
infection of cells bearing Fc receptors, a phenomenon termed antibody-dependent 
enhancement of infection (ADE) [7]. Therefore, an ideal candidate DEN vaccine should 
simultaneously provide long lasting protective immunity against all four DENV serotypes 
[3,10]. Currently, there are several tetravalent vaccine candidates in development, including 
mixtures of four different inactivated viruses, recombinant live attenuated viruses, protein 
subunit and DNA vaccines [11]. In this study, we investigated a live-attenuated DENV 
tetravalent vaccine (DENVax) consisting of infectious cDNA clone-derived DENV-2 
PDK-53, and three chimeric viruses containing the preM and E genes of DENV-1, -3, or -4 
in the DENV-2 PDK-53 genome background [12–15]. The original cell culture derived 
DENV-2 PDK-53 vaccine virus has been tested as a monovalent vaccine in Phase 1 and as a 
component of a tetravalent vaccine in Phase 2 clinical trials. The DENV-2 PDK-53 vaccine 
was shown to be well-tolerated and to generate long-lasting neutralizing antibody and cell-
mediated immune responses to DENV-2 [16–21]. The mutations necessary and sufficient for 
the attenuated phenotype of DENV-2 PDK-53 virus genetically identified were shown to 
reside outside of the structural gene regions of the viral genome [14,15].
The main objectives of this study were: (i) to test the safety and further characterize the 
immunogenic profile of monovalent DENVax vaccines in AG129 mice, (ii) examine the 
effect of immunization with different component ratios of tetravalent DENVax on the 
hierarchy of neutralizing antibody responses, and (iii) evaluate the protective efficacy of 
monovalent DENVax vaccines or various tetravalent DENVax formulations against 
intraperitoneal challenge with a lethal dose of DENV-1 Mochizuki or mouse brain adapted 
DENV-2 New Guinea C virus. These studies supported the initiation of Phase I clinical trials 
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of DENVax to assess the safety of the vaccine as well as measure the immune responses 
after administration to healthy adults.
2. Materials and methods
2.1. Viruses and cell culture
Wild-type DENV-1 16007, DENV-2 16681, DENV-3 16562, and DENV-4 1036 viruses 
were obtained from the Division of Vector-Borne Diseases, Centers for Disease Control and 
Prevention (CDC), Fort Collins, CO. DENVs were grown in Vero cells in Dulbecco’s 
modified minimal essential medium (DMEM) containing penicillin-streptomycin.
2.2. DENVax viruses
The DENVax viruses consist of cDNA clone-derived DENV- 2 VV45R virus (based on 
genome of DENV-2 PDK-53), and the DENV-2VV45R-based chimeras expressing the prM 
and E genes of wild-type (wt) DENV-1 16007, DENV-3 16562 or DENV-4 1036. The 
construction and characterization of these viruses has been previously reported [12–15]. To 
complete preclinical and clinical development of DENVax, new viral stocks were generated 
by introducing RNAs transcribed from infectious cDNA clones (pD2-VV45R [15] and 
chimeric pD2/1V, /3V, and/4V plasmids [12]) into certified vaccine production Vero cells 
under Good Manufacturing Practice (GMP) conditions at Shantha Biotechnics, Ltd., 
Hyderabad, India. The resulting re-derived viruses were amplified, plaque purified, 
characterized and sequenced. Based on these analyses, a formal pre-master virus seed was 
chosen and then was amplified to generate the master virus seed for each DENVax serotype 
(Huang et al., manuscript in preparation). For the studies reported here we used either GMP 
quality master seed virus stocks or surrogate master seed prepared in our laboratory from 
individual pre-master cGMP seeds. These surrogate master seed viruses were grown in 
serum-free media under vaccine production conditions.
Three tetravalent vaccine formulations containing different ratios of the individual DENVax 
components were prepared. For each, surrogate vaccine preparations were mixed into a 
novel FTA diluent (final concentration 1% F127 polyoxyethylene–polyoxypropylene block 
copolymer), 15% tre-halose, and 0.1% human serum albumin) that has shown to improve 
the thermal stability of these DENVax vaccine viruses [22]. Formulation 1 (3333) contained 
103 plaque forming units (pfu) of each of the four DENVax viruses per dose. Formulation 2 
(3355) was prepared to contain 103 pfu each of DENVax-1 and DENVax-2, and 105 pfu 
each of DENVax-3 and DENVax-4 per dose. Formulation 3 (5555) contained 105 pfu of 
each of the four DENVax viruses per dose. To validate the virus concentrations, the titer of 
each DENVax virus was determined by an immunofocus assay described below.
2.3. Telemetry
For measurement of body temperature, animals were implanted subcutaneously with BMDS 
IPTT-300 transponder (chips), purchased from BioMedic Data Systems, Inc. (BMDS, 
Seaford, DE) two to three days prior to start of the study and were monitored for signs of 
infection or migration of the transponder. Chips were scanned using a DAS-6007 
transponder reader (BMDS).
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Treatment of animals was in accordance with the University of Wisconsin-Madison 
Standard Operating Procedures, which adhere to the regulations outlined in the USDA 
Animal Welfare Act (9 CFR Parts 1, 2 and 3) and the conditions specified in the Guide for 
the Care and Use of Laboratory Animals (1996). All animal study protocols were approved 
by the UW Institutional Animal Care and Use Committee. AG129 mice (supplied by B & K 
Universal Ltd., UK) lack the IFN-α/β and IFN-γ receptor genes and have been successfully 
used as a mouse model for DENV studies [12,13,23]. Although they possess IFN receptor 
deficiencies, AG129 mice otherwise exhibit immunological competence and are able to 
mount antibody and cellular immunity to variety of pathogens [24].
Immunogenicity studies with monovalent DENVax vaccines were conducted in groups of 5–
8 week-old AG129 mice (n = 6) by subcutaneously (SC) injecting a dose of 105 pfu of each 
of the individual DENVax vaccines in 0.5 ml. Control mice were injected by the same route 
with PBS. All animals received primary and secondary immunizations on days 0 and 42, 
respectively. Mice were monitored daily for morbidity and mortality. Serum samples 
collected at days 0, 42, and 56 were tested for DENV serotype-specific neutralizing 
antibodies.
A subsequent study evaluated the protective capacity of each monovalent DENVax vaccine 
using non-GMP surrogate vaccine preparations. Groups of ten 8–9 week old AG129 mice 
received a SC injection of 0.1 ml containing 105 pfu of each surrogate master seed virus. 
Control mice were inoculated via the same route with FTA (the virus diluent). At five weeks 
after the single vaccine administration each group was split into two sub-groups of five mice 
and were challenged by intraperitoneal (IP) administration of 106 pfu of DENV-1 
Mochizuki or DENV-2 New Guinea C viruses in 0.1 ml. Following challenge, all mice were 
monitored twice a day for five weeks for morbidity (weight loss, temperature, neurological 
signs), and survival rates were recorded.
The immunogenicity and protective efficacy of tetravalent DEN-Vax formulations 
(Formulation 1, 2 and 3) were tested in groups of eight 5–8 week old AG129 mice. Each of 
the three formulations and the FTA diluent was administered SC on day 0 and 42. Viremia 
levels were measured in samples collected on day 3 post-primary vaccination, the peak of 
dengue virus replication in the AG129 mouse model [25]. Serum neutralizing antibody 
responses against all four serotypes were measured in individual blood samples collected on 
days 30 and 56 post-priming. On day 56 each group of eight mice was sub-divided into two 
groups of four mice and challenged IP with 106 pfu of DENV-1 Mochizuki or DENV-2 New 
Guinea C virus. Animals were monitored daily for three weeks for clinical signs of disease 
and survival rates were recorded.
2.5. Virus plaque titration and immune focus assay
Virus plaque forming units were measured by plaque titration performed in double agarose 
overlays in six-well plates of conflu-ent Vero cells as previously described [12]. The plaque 
titration was performed for each monovalent DENVax virus. For tetravalent DENVax 
formulations and viremia measurements of animals vaccinated with tetravalent DENVax, we 
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performed immune focus assay using serotype-specific monoclonal antibodies (MAbs), 1F1 
(DENV-1), 3H5 (DENV-2), 8A-1 (DENV-3), and 1H10 (DENV-4) to differentiate titers for 
each DENVax serotype. The immune focus assay was conducted in confluent Vero cells in 
6-well plates. Cells were adsorbed with serially diluted samples for 1.5 h at 37 °C and 
overlaid with 3 ml/well of YE-LAH medium [12] containing 0.7% high viscosity 
carboxymethylcellulose (CMC) (Sigma). After 7-day incubation at 37 °C with 5% CO2, 
overlay was aspirated, and cell sheets were washed 3 times with PBS before they were fixed 
by adding cold 85% acetone or 100% methanol for 30 min at −20 °C. After fixation, plates 
were air dried, washed once with PBS, and blocked with a buffer containing 2.5% (w/v) 
nonfat dry milk, 0.5% Triton X-100, 0.05% Tween-20 in PBS at 37 °C for 30 min. After 
blocking, cells were incubated with diluted DENV serotype-specific MAbs in the blocking 
buffer at 37 °C for 1 h or 4 °C for overnight, washed 3 times with washing buffer (0.05% 
Tween-20 in PBS), and incubated with diluted alkaline phosphatase-conjugated affinity pure 
goat anti-mouse IgG (Jack-son Immuno Research Laboratories) at 37 °C for 45 min. Plates 
were washed three times again with washing buffers and stained with 0.4 ml/well of 1-Step 
NBT/BCIP plus suppressor (Pierce). Immune foci were visible after 20 min at room 
temperature and color development was stopped by washing the plates with water within an 
hour to avoid dark cell background. Immune foci were counted to calculate the immune 
focus units (ifu)/ml of the input samples.
2.6. Neutralization assays
Serum samples collected for neutralization assay were heated at 56 °C for 30 min to 
inactivate complement and possible adventitious agents. Heat-inactivated sera were tested 
for neutralizing antibodies by the 50% plaque reduction neutralization test (PRNT50) as 
previously described [12]. The neutralizing antibody titer was identified as the highest serum 
dilution that reduced the input number of virus plaques by at least 50% (PRNT50). All 
samples were assayed in duplicate. The input virus numbers were calculated by back 
titration with 2-fold serial dilutions of the input viruses in each assay. Neutralizing antibody 
titers of less than 10 were considered negative and were assigned an inverse titer of 1 for 
calculation purposes. Duplicate PRNT50 values for each sample were geometrically 
averaged and geometric mean titers (GMT) were calculated for each group of animals.
3. Results
3.1. Safety, immunogenicity and antigenic specificity of monovalent chimeric DENVax 
vaccines
Groups of AG129 mice were immunized with monovalent chimeric DENVax vaccines and 
monitored for clinical signs of infection, weight loss and temperature changes. After 
vaccination there was no mortality and all animals showed no evidence of abnormal 
elevation of body temperatures or weight loss as compared to the control groups. The mean 
body weights and temperature of mice vaccinated with each monovalent DENVax vaccine 
are presented in Tables 1 and 2, respectively.
Following vaccination with each monovalent DENVax, serum samples collected after the 
primary and secondary immunization were tested for serotype-specific neutralizing antibody 
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responses against the four DENV serotypes. As shown in Table 3, monovalent vaccines 
elicited strong primary and secondary neutralizing antibody responses against their wild-
type homologous virus strains. In addition, all monovalent vaccines elicited low levels of 
cross-neutralizing antibodies to the three other serotypes with the highest cross-neutralizing 
reactivity observed against DENV-3 in the DENVax-1, DENVax-2, and DENVax-4 
immunization groups. A weak anti-DENV-3 neutralizing activity in the serum of PBS 
immunized mice, suggesting possible non-specific serum factors that might neutralize this 
virus.
3.2. Protective efficacy of monovalent chimeric DENVax vaccines against homologous or 
heterologous DENV challenge
A single immunization of AG129 mice with each of the monovalent DENVax vaccine 
formulations provided complete protection against lethal challenge with wt DENV-1 
Mochizuki virus, administered IP at five weeks post priming (Fig. 1A). Similarly, 
monovalent chimeric DENVax-1 or DENVax-2 conferred 100% protection against lethal IP 
challenge with DENV-2 New Guinea C virus. Immunization with DENVax-3 provided 
significant protection (P = 0.0031 based on a Log-rank test) from challenge with DENV-2 
(Fig. 1B). Interestingly, while vaccination with monovalent DENVax-4 did not protect 
against DENV-2 challenge, the median survival time was significantly longer (P = 0.0067 
based on a Log-rank test) than that of non-vaccinated control animals (32 and 7.5 days, 
respectively). None of the vaccinated animals displayed any sign of morbidity. In contrast, 
control infected animals succumbed to infection after early signs of morbidity (ruffled coat 
and/or hunched posture) followed by paralysis and sudden death or humane euthanasia.
3.3. Viremia following immunization with the tetravalent DENVax vaccine formulations
Mice were immunized with the three formulations of the four DENVax strains. In one study, 
the replication of DENVax viruses was assessed by measuring viremia in blood samples 
collected shortly after the primary immunization. The magnitude of viremia following SC 
immunization with DENVax Formulation 2 (103, 103, 105, 105 of DENVax-1, -2, -3 and -4, 
respectively) and DENVax Formulation 3 (105 of each strain) varied between the four 
vaccine strains and were dependent on the ratio of component chimeric viruses. After 
administration of Formulation 3, the DENVax-2 showed the highest viremia with detectable 
levels in all 8 mice of average value 3.36 log10 ifu/ml followed by the DENVax-1 (6 out of 
8 mice), DENVax-3 (4 out of 8 mice) and DENVax-4 (1 out of 8 mice) with average values 
of 2.0, 1.3, and 0.3 log10 ifu/ml, respectively (Fig. 2B). After administration of Formulation 
2 there were only two mice that had detectable viremia for DENVax-2 (average value 0.62 
log10 ifu/ml), and 7 out of 8 mice for DENVax-3 (average value 2.78 log10 ifu/ml) (Fig. 
2A). No mice demonstrated detectable DENVax-1 or DENVax-4 viremia. Comparison of 
viremia levels between formulation 2 and 3 for each monovalent DENVax vaccine using 
one-way ANOVA test reveal significant differences for DENVax-1 (P = 0.0005), DENVax- 
2 (P < 0.0001) and DENVax-3 (P = 0.0424) but not for DENVax-4 (P = 0.3343). Viremia 
after administration of DENVax Formulation 1 was not assessed due to insufficient quantity 
of available serum samples.
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3.4. Neutralizing antibody responses elicited by different formulations of tetravalent 
DENVax vaccine
Immunization of AG129 mice with formulations containing different ratios of the four 
DENVax viruses (Formulations 1, 2 or 3) elicited neutralizing antibody responses against all 
four serotypes (Fig. 3). After the booster immunization the neutralizing antibody response 
induced by Formulation 3 was dominated by the anti-DENV-2 and DENV-1 response 
followed by the anti-DENV-3 and anti-DENV-4 response. In Formulation 2, the neutralizing 
antibody response was dominated by the anti-DENV-3 and followed by anti-DENV-1, anti-
DENV-2, and anti-DENV-4 response. Finally, neutralizing antibody responses elicited by 
Formulation 1 were lower than those induced by Formulations 2 and 3. It is interesting to 
point out that following a booster injection with Formulation 1, there was no clear boosting 
effect on DENV-1 and DENV-3 neutralizing antibody titers on sampling day 56, which 
could be accounted to differences in the kinetics of antibody responses to these two 
serotypes. In all tested formulations, the DENVax-4 vaccine was the least immunogenic of 
the DENVax vaccine components (Fig. 3). Overall, Formulation 3 gave significantly higher 
neutralizing antibody responses to all four serotypes than formulations 1 and 2 (P < 0.05) for 
both sampling days using repeated measures by ANOVA test.
3.5. Ability of the tetravalent DENVax formulations to protect against challenge of AG129 
mice with wild-type DENV-1 and DENV-2
Two weeks after the second DENVax administration all tetravalent-vaccinated and control 
mice were subdivided into two groups and challenged with a lethal dose of DENV-1 
Mochizuki (Fig. 4A) or DENV-2 New Guinea C viruses (Fig. 4B). All DENVax immunized 
mice survived infection while control animals succumbed to infection between 6 and 11 
days after challenge. All vaccinated animals failed to show any clinical signs of disease 
following viral challenge independent of the DENVax formulation. In contrast, by day 5 
after challenge all control animals showed clinical signs of illness (e.g. ruffled coat, hunched 
posture and hind limb paralysis). On day 6 post-challenge, one animal from each of the 
challenged groups died and, by day 11 post-challenge, all control animals had succumbed to 
infection or been euthanized (Fig. 4A and B).
4. Discussion
The development of an effective vaccine against DENVs represents an important step 
towards the prevention and control of this global emerging disease. Current efforts are 
focused on the development of tetravalent vaccines that simultaneously provide protection 
against all four DENV serotypes [3,10]. In this study we tested a novel tetravalent DENVax 
that consists of the live, attenuated viruses based on recombinant DENV-2 PDK-53.
The safety, immunogenicity and efficacy of monovalent DENVax were evaluated in the 
AG129 mouse model. All four vaccines were well tolerated with no signs of morbidity, 
weight loss or febrile response. After priming each monovalent vaccine elicited a robust 
neutralizing antibody response to the homologous virus and these responses were further 
elevated following a booster injection with the exception of DENVax-2. In general, 
DENVax-1, -2, and -3 were very immunogenic as compared to DENVax-4 which was the 
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least immunogenic vaccine candidate. Neutralizing antibodies to each monovalent DENVax 
vaccine were weakly cross-reactive with non-homologous DENV-1, DENV-2, and 
DENV-4, while demonstrating high cross-reactivity against DENV-3. Such cross reactive 
epitopes are normally located at domains I and II and elicit low avidity cross-reactive 
neutralizing antibody responses although cross-reactive epitopes have been also identified in 
DIII [26].
Antibodies can provide long-term protection against the serotype responsible for the 
homologous challenge virus and cross-reactive neutralizing antibodies may contribute to 
short-term protection against heterologous virus challenge. As indicated by our data, AG129 
mice immune to each monovalent DENVax vaccine were protected against homologous and 
heterologous DENV challenge with the exception of DENVax-4 which conferred partial 
protection against DENV-2 virus. It is still not clear what levels of cross-neutralizing 
antibodies are required for protection and to what degree this protection is similar to that 
elicited by the homologous virus. Our data are consistent with studies by Kyle et al. [27] 
highlighting the role of antibodies in heterologous protection against secondary DENV 
infection in the AG129 mouse model. The low-level cross-neutralizing antibodies might 
exert their effect in concert with cross-reactive anti-virus antibodies that induce 
conformational changes that increase the avidity to closely related antibodies. Alternatively, 
cross reactive antibodies might inhibit heterologous virus uptake by Fcγ receptors through 
the formation of viral aggregates hence preventing antibody-dependent enhancement of 
DENV infection [28]. Even weak levels of cross-neutralizing antibodies may be sufficient to 
confer protection alone or together with induced cross-reactive effector T cells. In particular, 
the non-structural NS3 protein could be a potential source of such cross-reactive CTL 
epitopes [29,30]. We are currently pursuing a systematic study to assess the functional role 
of passively transferred antibodies in protection against homologous and/or heterologous 
DENV challenge in conjunction with adoptive transfer studies. Nevertheless, irrespective of 
which arm of adaptive immunity is involved in protection afforded by each monovalent 
DENVax vaccine, our findings highlight the capability of candidate DENVax vaccine 
viruses to afford at least a short-term protection against heterologous virus challenge. In this 
mouse model we are unable to conduct long-term vaccine efficacy studies against 
homologous or heterologous DENV challenge since mice become resistant with age and do 
not succumb to infection. An alternative approach to evaluate the long-term cross protective 
efficacy of each monovalent DENVax vaccine could be based on measuring virus 
replication in tissues following challenge, as indicated by Kyle et al. [27] and currently we 
are pursuing this option.
Following priming with the tetravalent DENVax vaccine the profile of viremia was 
dependent on the ratio of component monovalent vaccine viruses. Viremia titers in DENVax 
Formulation 2 (3355) were generally low. Only two mice out of eight had detectable viremia 
to DENVax-2 and seven out of eight against DENVax-3. In contrast, detectable viremia 
against all DENVax vaccines was measured in mice immunized with the DENVax 
Formulation 3 (5555). In the current study direct evidence for DENVax-4 viremia in mice 
was absent (with the exception of one mouse in the Formulation 3); however, AG129 mice 
mounted an anti-DENV-4 neutralizing antibody response, irrespective of the DENVax 
vaccine ratio. A previous study has shown that the chimeric DENVax-4 has a relatively 
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slower replication than the other three DENVax in cell culture [12]. Therefore, it is very 
likely that on day 3 post immunization measuring viremia may be too early for DENVax-4 
infection. Due to the limited amount and frequency of serum samples allowed to be 
collected in animals, blood samples were collected after priming on day 3 based on previous 
study of dengue infection in AG129 mice [25]. In addition, previous studies using a 
chimeric yellow fever-DENV tetravalent vaccine in non-human primates [31] and our own 
studies conducted with DENVax in this species [32] have shown that there is not necessarily 
a direct correlation of viremia with neutralizing antibody responses in animals immunized 
with the live attenuated DEN vaccine.
All tested DENVax formulations were immunogenic and elicited primary and secondary 
neutralizing antibody responses to all four DEN viruses. However, responses to certain 
serotypes were more dominant. This finding is consistent with studies showing that 
antibodies are sometimes preferentially solicited against one or two dominant serotypes due 
to intrinsic differences in immunogenicity and/or virus interference [33]. In addition, 
DENVax-immune mice were protected against challenge with DENV-1 or DENV-2 
consistent with previous studies demonstrating the efficacy of tetravalent DENV-2 PDK-53 
based recombinant vaccine in the AG129 mouse model [12,13]. Immunogenicity studies 
conducted in previous reports [12,13] were through IP immunization. In this study, we 
showed that the SC route was also very effective for immunizing AG129 mice with 
DENVax. Due to lack of any strains of wt DENV-3 and DENV-4 that have been shown to 
be lethal for AG129 mice, we were unable to directly determine protective efficacies of the 
tetravalent DENVax formulations against lethal challenge with these viruses. However, 
given that all tetravalent mixtures elicited anti-DENV-3 and DENV-4 neutralizing titers, 
particularly after the boost, it is anticipated that they should be protective. In addition, a 
single monovalent DENVax-3 or DENVax-4 provided full or partial protection against 
heterogonous wt DENV-1 or DENV-2 lethal challenge (Fig. 1A and B), indicating these two 
vaccine components should be able to protect against homologous wt DENV-3 or DENV-4 
challenge as well.
In conclusion, although immunogenicity studies in mice may not accurately reflect the 
human response to DENV infection, the findings of this study highlight the safety, 
immunogenicity and protective efficacy profile of the monovalent and various tetravalent 
DENVax formulations in a novel FTA formula by the subcutaneous route in one of the most 
accepted DENV mouse model, the AG129 mice. These findings support further clinical 
development and optimization of the tetravalent DENVax.
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Protection afforded after vaccination with a single dose of monovalent DENVax. Groups of 
10 AG129 mice were immunized SC with each of the monovalent DENVax vaccines. 
Additional control groups were injected by the same route only with FTA. On day 35 all 
animals were split into two groups of five animals per group and were challenged IP with 
106 pfu of DENV-1 Mochizuki virus (A) or 106 pfu of mouse adapted DENV-2 New Guinea 
C virus (B). Animals were monitored daily for clinical signs of disease for five weeks and 
survival rates were recorded.
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Viremia following vaccination with monovalent DENVax viruses. Groups of eight AG129 
mice were immunized SC with DENVax Formulation 2 (A) or 3 (B). On day three post 
vaccination blood samples were collected and serum from each individual mouse was 
analyzed for viremia by immune focus assay with DENV serotype-specific MAbs.
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Neutralizing antibody responses against all four DEN virus serotypes following 
immunization with DENVax Formulations 1, 2 and 3. Groups of eight AG129 mice were 
immunized SC with DENVax bearing different ratios of component vaccine viruses. 
Additional control groups were injected by the same route only with FTA. A booster SC 
injection of the same range of doses was given on day 42 post-priming. Blood samples were 
collected at 30 and 56 days post-primary vaccination and used to measure the neutralizing 
antibody response to the four DEN viruses by PRNT50. Bars represent geometric mean titer 
(GMT) ± SE. Geometric mean titer of neutralizing antibody responses elicited in control 
mice immunized with FTA were lower than 40 against all four DEN virus serotypes.
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Protection afforded after vaccination with different DENVax formulations. Groups of eight 
AG129 mice were immunized subcutaneously with DENVax bearing different ratios of 
component vaccine viruses. Additional control groups were injected by the same route only 
with FTA. A booster SC injection of the same range of doses was given on day 42 post-
priming. On day 70 all animals were split into two groups of four animals per group and 
were challenged intraperitoneally with 106 pfu of DENV-1 Mochizuki virus (A) or 106 pfu 
of mouse adapted DENV-2 New Guinea C virus (B). Animals were monitored daily for 
clinical signs of disease for three weeks and survival rates were recorded.
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